BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) announced today it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib as an arm in NIAID’s Adaptive COVID-19 Treatment Trial.

DiaSorin (FTSE MIB: DIA) announced today the completion of the studies conducted at the Policlinico San Matteo in Pavia to support the launch of a new serological and high-processing volume test to detect the presence of antibodies in patients infected with the SARS-CoV-2.

Dr. Christopher Murray, Director of the Institute for Health Metrics and Evaluation at the University of Washington’s School of Medicine, will host a press briefing on Saturday, April 11, at 11 am / 4 pm on the latest forecasts in the U.S., the U.K. and Europe regarding deaths and hospital usage related to COVID-19.

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NMC Health Plc between March 13, 2016 and March 10, 2020, inclusive, of the important May 11, 2020 lead plaintiff deadline in the securities class action first filed by the firm.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration

The American Association of Nurse Anesthetists announced today The Department of Health and Human Services began the delivery of the initial $30 billion in relief funding to healthcare providers in support of the national response to COVID-19 as part of the distribution of the $100 billion provider relief fund provided for in the Coronavirus Aid, Relief, and Economic Security Act recently passed by Congress.

The document attached to this press release is a statement from Andre Watson, a scientist who is the founder, chairman and CEO of Ligandal, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neon Therapeutics, Inc. (“NTGN” or the “Company”) (NASDAQ: NTGN) in connection with the proposed acquisition of the Company by BioNTech (“BNTX”) (NASDAQ: BNTX).